01Feb 2023
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

The study aims to report two phase I studies of the novel subcutaneous glucagon‐like peptide‐1 receptor/glucagon receptor (GLP‐1R/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight/obesity. The results of the study showed that in the SRD study (N = 24), mean body weight decreased with increasing BI 456906 dose. In the MRD study, the maximum decreases in placebo‐corrected mean body weight were at week 6 and week 16. BI 456906 reduced plasma amino acids and glucagon, indicating target engagement at GCGRs and GLP‐1Rs. Drug‐related adverse events (AEs) increased with BI 456906 dose. The most frequent drug‐related AE with SRDs was decreased appetite, and two subjects (8.3%) did not complete the trial because of AEs. From the results, it can be concluded that BI 456906 produced a placebo‐corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight/obesity.

  • #endo-diabetology

Like

Save

Share